Table 3.
Variable | Univariate Model | Multivariate Full Model | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
PFS | ||||||
Treatment arm | ||||||
BAY 43-9006 and IFN | 0.848 | 0.507–1.418 | .5289 | 0.847 | 0.506–1.416 | .5264 |
BAY 43-9006 | 1.000 | 1.000 | ||||
ECOG performance status | ||||||
1 | 1.589 | 0.937–2.694 | .0859 | 1.379 | 0.784–2.425 | .2641 |
0 | 1.000 | 1.000 | ||||
Anemia | ||||||
Yes | 1.657 | 0.982–2.793 | .0583 | 1.493 | 0.853–2.613 | .1607 |
No | 1.000 | 1.000 | ||||
OS | ||||||
Treatment arm | ||||||
BAY 43-9006 and IFN | 1.945 | 0.837–4.517 | .1219 | 2.172 | 0.921–5.122 | .0764 |
BAY 43-9006 | 1.000 | 1.000 | ||||
ECOG performance status | ||||||
1 | 3.055 | 1.333–7.000 | .0083 | 2.535 | 1.037–6.197 | .0414 |
0 | 1.000 | 1.000 | ||||
Anemia | ||||||
Yes | 3.272 | 1.393–7.684 | .0065 | 2.475 | 1.000–6.129 | .0501 |
No | 1.000 | 1.000 |
HR indicates hazard ratio; CI, confidence interval; PFS, progression-free survival; biaryl urea 43-9006, sorafenib; IFN, interferon alfa; ECOG, Eastern Cooperative Oncology Group; OS, overall survival.